Mono-N-terminal poly(ethylene glycol)-protein conjugates

Advanced Drug Delivery Reviews

Volumn 54, Issue 4, 2002, Pages 477-485

  Kinstler, Olaf ^a   Molineux, Graham ^a   Treuheit, Michael ^a   Ladd, David ^a   Gegg, Colin ^a  

^a AMGEN INC   (United States)

Author keywords

Poly(ethylene glycol); Polymer modified proteins; Site specific conjugation; Therapeutic proteins

Indexed keywords

ALDEHYDES; ALKYLATION; POLYETHYLENE GLYCOLS;

THERAPEUTIC VALUES;

PROTEINS;

MACROGOL DERIVATIVE; MONO N TERMINAL POLYETHYLENE GLYCOL PROTEIN CONJUGATE; MONO N TERMINAL POLYETHYLENE GLYCOL RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR CONJUGATE; MONO N TERMINAL POLYETHYLENE GLYCOL RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR CONJUGATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ALKYLATION; ANALYTIC METHOD; CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ALKYLATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; HYDROGEN-ION CONCENTRATION; MUTAGENESIS, SITE-DIRECTED; POLYETHYLENE GLYCOLS; PROTEINS; RECOMBINANT PROTEINS; THROMBOPOIETIN;

EID: 0037124498     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00023-6     Document Type: Article

References (63)

1. Therapeutic antibody fragments with prolonged in vivo half-lives
2. Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity
3. Transglutaminase-mediated dual and site-specific incorporation of poly(ethylene glycol) derivatives into chimeric interleukin-2
4. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins
5. Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules
6. Polyethylene glycol-modified chimeric toxin composed of transforming growth factor α and Pseudomonas exotoxin
7. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol
8. Pseudomonas exotoxin A mutants: Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner
9. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity
10. Pseudomonas exotoxin A mutants: Replacement of surface exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner
11. Laboratory synthesis of polyethylene glycol derivatives
12. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates
13. Rational design of a potent, long-lasting form of interferon: A 40-kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C
14. PEG-treated enzymes are nearly invisible to the immune system
15. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds
16. Site protected PEGylation of recombinant tumor necrosis factor receptor
17. Synthesis and physiochemical properties of protein conjugates with water-soluble poly(alkylene oxides)
18. Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity
19. Improvement of oxygen-carrying properties of human hemoglobin by chemical modification with a benzene hexacarboxylate-monosubstituted polyoxyethylene
20. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation and homology modeling
21. Subtiligase: A tool for semisynthesis of proteins
22. A general method for highly selective crosslinking of unprotected polypeptides via pH-controlled modification of N-terminal α-amino groups
23. Site-directed PEGylation of recombinant interleukin-2 at its glycosylation site
24. Labeling glycoconjugates with hydrazide reagents
25. Studies on the rate and control of antibody oxidation by periodate
26. Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments
27. Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation
28. Reductive alkylation of proteins
29. Reactive groups of proteins and their modifying agents
30. Filgrastim (r-metHuG-CSF): The first 10 years
31. Characterization and stability of N-terminally pegylated Rhg-CSF
32. New sustained-duration form of neupogen
33. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans
34. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats
35. Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients
36. Pharmacokinetics (PK) of human granulocyte colony stimulating factor (G-CSF) in patients with neutropenia using a mixed effects model
37. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rats
38. Cytokinetic model of rmethHuG-CSF-SD/01 (SD/01) mediated granulopoiesis and the 'self-regulation' of SD/01 elimination in non-small cell lung cancer (NSCLC)
39. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy
40. Demonstration and some properties of human thrombopoietin in thrombocythemic sera
41. Cloning and expression of murine thrombopoietin cDNA and stimulation of platlet production in vivo
42. Purification and characterization of thrombopoietin
43. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand
44. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platlet production
45. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
46. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor
47. Regulation of TPO mRNA expression and protein production TPO gene regulation appears post transcriptional, and endogenous levels are inversely correlated to megakaryocyte mass and circulating platlet count
48. Regulation of platlet production 'Hypersplenism' in the experimental animal
49. Pharmacokinetic analysis of Pegylated megakaryocyte growth and development factor in humans
50. PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor
51. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice
52. The acute effect of Pegylated recombinant human growth and development factor (PEG-MGDF) on platlet counts in normal and splenectomized Sprague-Dawley rats after a single intravenous dose
53. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice
54. Effects of megakaryocyte growth and development factor on platlet production, platlet life span, and platlet function in healthy human volunteers
55. The biological significance of truncated and full-length forms of mp1 ligand